Mydecine applies for its own NASDAQ listing.
PSYK Commences Trading, Tracking The North American Psychedelics Index
PSYK, the first psychedelics ETF, commences trading today on Canada's Neo Exchange.
Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US
Field Trip continues its U.S. expansion with opening of a new clinic in Atlanta.
Re-Release: Psyched Wellness Upsizes Previously Announced Bought Deal Offering
Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.
Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity
Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.
Numinus Announces Listing of New Warrants
Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.
Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond
The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
Entheon announces a new partnership to advance its psychedelic drug R&D.
CYBIN Announces Upsize to Previously Announced Bought Deal Offering
Cybin's bought deal financing has been upsized to CAD$30 million.
Cybin Announces CDN$20 Million Bought Deal Offering
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.
